Inflammation indices in prostate cancer patients

Prostate cancer is the leading cause of worldwide incidence of neoplastic disease. On the other hand, inflammation plays a vital role in the spread of cancer cells. The aim of this work was to determine whether NLR and PLR inflammatory indices in prostate cancer patients have a prognostic value for survival and/or predictive of the effect of CIMAVAX-EGF and Nimotuzumab immunotherapy treatments. The results of the present investigation showed that the NLR index decreased and the PLR index increased over time for all treatments. A low NLR proved to be prognostic for the survival of patients in the CIMAvax-EGF trial. Also, the PLR index showed that its predictive value is due to the fact that patients with high PLR treated with Nimotuzumab have a longer survival than controls. The present work shows that the NLR and PLR indices are an accessible and cost-effective laboratory tool that provides prognostic and predictive information for prostate cancer and associated immunotherapeutic treatments.

Autorentext

Licenciatura em Matemática, Universidade de Havana, 1991. Licenciatura em Cibernética, Universidade de Havana, 1995. Mestrado. Estatística e Probabilidade, Universidade de Havana, 2000 Investigador Assistente. 2002. Mestrado. Estatística Aplicada, Universidade de Hasselt, Bélgica, 2003. Tecnólogo de primeiro nível. 2010. Professor Assistente, 2015. Doutoramento em Ciências, 2022.